Even so, he said, combined with a planned $50 monthly Medicare copay for some GLP-1s that would cover many but not all Medicare beneficiaries with obesity, and possible Medicaid coverage, the deal "is a great step in the right direction to allow patients to get the care they need." Medicare, a federal program for people 65 and over and younger people with certain disabilities, currently does not cover GLP-1s for weight loss, nor does Medicaid in most states, including New York
Understanding how to maintain benefits after stopping tirzepatide and how to wean off properly matters because some benefits may persist after discontinuation (improved metabolic health, resolved sleep apnea) while others may diminish (direct anti-inflammatory effects, lipid improvements)
They may not be as effective for maximum weight loss as initial therapy but could be excellent for weight-loss maintenance, which is a different and arguably much more important destination for lasting health benefits. Eli Lilly will test just that, according to recently posted study plans on a federal database of clinical trials
Some of these compounds not only directly affect TC cells by reducing their viability, proliferation, or their ability to migrate to the metastatic side, but also indirectly affect cancer progression by regulating the secretion of pro-tumorigenic chemokines in the TC microenvironment
